Chinese PE Multimodality Imaging Artificial Intelligence Study
Launched by CHINA-JAPAN FRIENDSHIP HOSPITAL · Jul 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a clinical trial that aims to improve the diagnosis and treatment of pulmonary embolism (PE), a serious condition where a blood clot blocks blood flow to the lungs. This study will use advanced imaging techniques and artificial intelligence to find new ways to identify and understand PE, which could help doctors make quicker and more accurate decisions about patient care.
If you are 14 years or older and have been suspected of having PE, you may be eligible to participate. However, pregnant women and those who do not want to follow up or have poor-quality imaging may not be included. Participants in this study can expect to undergo specific imaging tests, and their data will contribute to important research that could lead to better treatments for PE in the future. The study is currently recruiting participants across multiple centers in China.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 14 Years and older
- • Patients suspected of PE
- Exclusion Criteria:
- • Pregnant women
- • Refuse to follow up
- • Incomplete or discontinued imaging scans
- • Insufficient quality of image data to allow for analysis
About China Japan Friendship Hospital
China-Japan Friendship Hospital is a leading clinical research institution dedicated to advancing healthcare through innovative medical research and trials. Established as a collaborative effort between China and Japan, the hospital integrates cutting-edge technology with traditional medical practices, fostering a multidisciplinary approach to patient care and clinical studies. The institution is committed to enhancing therapeutic outcomes and improving patient safety while adhering to rigorous ethical standards. With a diverse team of experienced healthcare professionals and researchers, China-Japan Friendship Hospital plays a pivotal role in addressing global health challenges and contributing to medical knowledge through its extensive clinical trial programs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Zhenguo Zhai, PhD
Study Director
China-Japan Friendship Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported